Collectively, these findings were in keeping with an infection. On day 4, treatment with meropenem was started, since Klebsiella pneumoniae that was delicate to meropenem was detected on bronchoscopy and tracheal lavage performed on day time 2. Staphylococcus aureus, which was sensitive to an array of antimicrobials, was gathered from a sputum sample collected on admission. Acinetobacter was detected in a tracheal aspirate sample collected on the full day of death. No other pathogens were detected in respiratory specimens, and no bacterial growth was detected from bloodstream samples.Participants from the Siaya District in Nyanza Province of Western Kenya will be enrolled. ‘Despite the option of the BCG vaccine, two million males, women and children die from tuberculosis every full year. We urgently need a new TB vaccine to ensure effective and long-term TB protection,’ said Jim Connolly, CEO and President of the Aeras Global TB Vaccine Basis. ‘This medical trial represents a significant step in our collaboration among a global network of researchers and the people of Kenya, who continue being at high-risk for TB infection.’ Related StoriesNew initiative released to accelerate search for effective HIV vaccineResearchers reveal why malaria vaccine provides only moderate protection among vaccinated childrenKey part of MRSA vaccine puzzle unearthedIn 2004, Aeras and Crucell began jointly developing this vaccine candidate using Crucell’s AdVac – vaccine technology and PER.C6 – manufacturing technology.